-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-06-26
GH:NSD- (USD)
COMMON STOCK | Diagnostics & Research |
Last Closing
USD 29.39Change
-0.09 (-0.31)%Market Cap
USD 3.66BVolume
0.86MVerdict
Verdict
Values as of: 2024-06-26
COMMON STOCK | Diagnostics & Research |
Last Closing
USD 29.39Change
-0.09 (-0.31)%Market Cap
USD 3.66BVolume
0.86MVerdict
Verdict
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
IDXX | IDEXX Laboratories Inc |
-6.76 (-1.37%) |
USD 41.65B |
ICLR | ICON PLC |
+0.25 (+0.08%) |
USD 26.38B |
ILMN | Illumina Inc |
-2.08 (-1.95%) |
USD 17.24B |
NTRA | Natera Inc |
-1.72 (-1.56%) |
USD 13.49B |
MEDP | Medpace Holdings Inc |
-12.49 (-2.94%) |
USD 12.38B |
EXAS | EXACT Sciences Corporation |
-2.24 (-5.03%) |
USD 7.74B |
RDNT | RadNet Inc |
+0.02 (+0.03%) |
USD 4.31B |
NEOG | Neogen Corporation |
-0.33 (-2.07%) |
USD 3.63B |
SHC | Sotera Health Co |
-0.03 (-0.25%) |
USD 3.21B |
OLK | Olink Holding AB ADR |
+0.19 (+0.75%) |
USD 3.17B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
XMLH:F | Legal & General Ucits Etf.. | 2.42 % | 0.00 % |
+0.03 (+0.00%) |
USD 0.07B |
DOCT:SW | L&G Healthcare Breakthrou.. | 2.42 % | 0.00 % |
N/A |
USD 0.07B |
DOCG:LSE | L&G Healthcare Breakthrou.. | 1.86 % | 0.00 % |
+1.15 (+0.00%) |
USD 0.07B |
DOCT:LSE | L&G Healthcare Breakthrou.. | 1.86 % | 0.00 % |
-0.01 (0.00%) |
USD 0.07B |
HTEC | Robo Global® Healthcare .. | 0.00 % | 0.00 % |
-0.04 (0.00%) |
USD 0.06B |
XHS | SPDR® S&P Health Care Se.. | 0.00 % | 0.35 % |
-0.27 (0.00%) |
USD 0.08B |
XMLH:XETRA | L&G Healthcare Breakthrou.. | 0.00 % | 0.00 % |
N/A |
USD 0.07B |
Market Performance vs. Industry/Classification (Diagnostics & Research) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | 8.65% | 80% | B- | 74% | C | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 8.65% | 80% | B- | 73% | C | ||
Trailing 12 Months | |||||||
Capital Gain | -20.05% | 60% | D- | 37% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -20.05% | 60% | D- | 36% | F | ||
Trailing 5 Years | |||||||
Capital Gain | -65.96% | 41% | F | 22% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -65.96% | 41% | F | 21% | F | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | -11.18% | 40% | F | 26% | F | ||
Dividend Return | -11.18% | 38% | F | 25% | F | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 51.67% | 49% | F | 32% | F | ||
Risk Adjusted Return | -21.64% | 42% | F | 29% | F | ||
Market Capitalization | 3.66B | 86% | B+ | 86% | B+ |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers median on a price to book value basis.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The company had negative total cash flow in the most recent four quarters.
The company had negative total free cash flow in the most recent four quarters.
This stock has shown below median earnings growth in the previous 5 years compared to its sector